| Literature DB >> 35881195 |
Shallinie Thangadurai1, Morteza Bajgiran1, Sharvin Manickam1, Nethia Mohana-Kumaran1, Ghows Azzam2,3.
Abstract
CTP biosynthesis is carried out by two pathways: salvage and de novo. CTPsyn catalyzes the latter. The study of CTPsyn activity in mammalian cells began in the 1970s, and various fascinating discoveries were made regarding the role of CTPsyn in cancer and development. However, its ability to fit into a cellular serpent-like structure, termed 'cytoophidia,' was only discovered a decade ago by three independent groups of scientists. Although the self-assembly of CTPsyn into a filamentous structure is evolutionarily conserved, the enzyme activity upon this self-assembly varies in different species. CTPsyn is required for cellular development and homeostasis. Changes in the expression of CTPsyn cause developmental changes in Drosophila melanogaster. A high level of CTPsyn activity and formation of cytoophidia are often observed in rapidly proliferating cells such as in stem and cancer cells. Meanwhile, the deficiency of CTPsyn causes severe immunodeficiency leading to immunocompromised diseases caused by bacteria, viruses, and parasites, making CTPsyn an attractive therapeutic target. Here, we provide an overview of the role of CTPsyn in cellular and disease perspectives along with its potential as a drug target.Entities:
Keywords: CTP synthetase; CTPS; CTPsyn; Cytoophidium; Drosophila melanogaster; Filamentation; Rods and rings
Year: 2022 PMID: 35881195 PMCID: PMC9314535 DOI: 10.1007/s00418-022-02133-w
Source DB: PubMed Journal: Histochem Cell Biol ISSN: 0948-6143 Impact factor: 2.531
Fig. 1The de novo cytidine triphosphate (CTP) synthesis pathway. Schematic diagram of the de novo CTP (pyrimidine) synthesis pathway. CTP synthesis enzymes CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; UMP synthetase uridine monophosphate synthetase, UMP/CMP kinase cytidylate monophosphate kinase, CTP synthetase cytidine triphosphate synthetase. Created with BioRender.com
Fig. 2A Drosophila larval nervous system comprising ventral nerve cord, central brain, and optic lobes. At optic lobes, sequential transition of neuroepithelial (NE) stem cells to neuroblasts (NBs) occurs (in box). NE stem cells undergo symmetric cell division to expand the pool of cells and subsequently give rise to NBs that divide asymmetrically to produce ganglion mother cells, which undergo mitotic division to produce neuronal daughter cells. CTPsyn forms cytoophidia at the NE stem cell region of the optic lobe. Created with BioRender.com
Fig. 3The Drosophila intestinal stem cell. The intestinal stem cell niche houses the ISCs, which divide and give rise to committed progenitor EB cells. Then, the EB cells differentiate into EEs and ECs. It is made up of simple monolayer epithelium cells, and unlike mammalian TA cells, the EBs rarely divide. The midgut homeostasis is maintained by the replenishment of aged or damaged gut cells with the new ones (Jiang and Edgar 2011). The presence of CTPsyn cytoophidia was observed in ISCs and EBs. Created with BioRender.com
Fig. 4Proposed role of ENDU-2 and its interaction with CTPS-1 in regulating nucleotide metabolism and germ cell proliferation. In response to nucleotide deprivation and genotoxic stress in the intestine of Caenorhabditis elegans, ENDU-2 shuts down germline proliferation via inhibiting the phosphorylation of CTPS-1 by repressing the protein kinase A (PKA) pathway and histone deacetylase-1 (HDA-1) (Jia et al. 2020). Created with BioRender.com
Fig. 5Oogenesis in Drosophila. a Schematic diagram of the two ovaries of Drosophila that is made up of approximately 18 ovarioles. b Each of this ovarioles undergo 14 stages of development to from mature egg (st. 14) from germarium (st. 1). c The germarium contains SSCs and GSCs at the anterior end of ovariole. These GSCs divide asymmetrically to self-renew and to produce a daughter cell, cystoblast which then undergoes four rounds of asymmetric and incomplete mitoses to form germline cysts (16 cells) interconnected by ring canals. Only one from these cysts become oocyte which then develop into mature egg while the other 15 differentiate to become nurse cells. Meanwhile, the SSCs give rise to precursor follicle cells, and about 16 out of these precursor follicle cells, then become polar cells and stalk cells. The rest of the precursor follicle cells encysts cyst cells and become egg chamber. Created with BioRender.com
Fig. 6Spermatogenesis in Drosophila. The stem cell niche is maintained by 12 non-dividing somatic cells, called ‘hub,’ anchored with GSCs and CySCs. The stem cell niche's maintenance is tightly regulated by a cascade of genes and pathways. Each GSC was encysted by two CySCs. Upon asymmetric division, each GSC self-renews and gives rise to gonialblast (GB), and each CySC self-renews and gives rise to cyst cells (early cysts and late cysts) that encyst the germ cells throughout the spermatogenesis until they develop into spermatids. The GB undergoes four rounds of transit amplifying (TA) mitotic divisions to produce 16 interconnected (by ring canals) spermatogonial cells that differentiate into early spermatocytes, and these spermatocytes undergo meiosis to produce 64 haploid spermatids. They then undergo elongation and coiling to become mature spermatids. The box represents the region where cytoophidia is normally abundant. Created with BioRender.com
Fig. 7Model illustrating the putative pathways that CTPsyn is involved and the crosstalk between these signaling pathways in cancer metabolism. The pro-tumorigenic genes (depicted with *) regulates the assembly of CTPsyn cytoophidia. The de novo nucleotide synthesis is acutely modulated in cancer cells. Glycolysis, tricarboxylic acid (TCA) cycle, amino acid biosynthesis pathways, epidermal growth factor receptor (EGFR), Ras, insulin, and TOR signaling pathways interact with de novo purine and pyrimidine nucleotide synthesis pathways along with the activation of Myc oncogene to increase nucleotide synthesis to cater to the nucleotide dependency of uncontrolled cell proliferation and tissue growth in cancer cells. Created with BioRender.com
CTPsyn as a drug target for diseases caused by viruses, bacteria, and parasites
| Disease | Role of CTPsyn | Reference |
|---|---|---|
| Toxoplasmosis (caused by | (Narvaez-Ortiz et al. | |
| African sleeping sickness (caused by | (Hofer et al. | |
| Tuberculosis (caused by | Drug-resistant | (Esposito et al. |
| Covid-19 (caused by SARS-CoV-2) | CTPS1 is hijacked by SARS-CoV-2 to mute IFN induction to shut down downstream immune responses and to promote virus replication in the host cell. CTPS1 inhibitor molecules could restore the IFN induction and shortage of CTP impedes virus replication in infected cells. This makes CTPS1 as a potential antiviral therapy target that could resist SARS-CoV-2 variants via restoring innate immune response upon infection (Fig. | (Rao et al. |
| Infectious mononucleosis and cancers (caused by Epstein-Barr virus (EBV)) | Patients with CTPS1 deficiency often have high EBV viral loads due to impaired T-cell surveillance. CTPS1/2 could be a potential therapeutic target for lymphoproliferative diseases caused by EBV | (Hislop et al. |
| Pox virus infections | Carbodine [cyclopentyl cytosine (C-Cyd)] and cyclopentenyl cytosine (Ce-Cyd) are antiviral agents that inhibit CTPsyn activity. These inhibitors suppress RNA synthesis and induce cytotoxicity in proliferating cells | (Marquez et al. |
| Antibiotic resistance (by | To develop anti-infectives, PyrG, CTPsyn is targeted by isoquinoline compounds, which have a higher antibiotic effect on | (Emami et al. |
| Respiratory tract infection (RTI) (caused by | 2-(3-[3-oxo-1,2-Benzisothiazol-2(3H)-yl]phenylsulfonylamino) benzoic acid (compound G1) could be the potential anti-microbial agent that targets PyrG, CTPsyn. Compound G1 could compete with ATP and/or UTP to bind with PyrG in order to inhibit CTPsyn activity. It was able to have anti-microbial property against different RTI causing bacteria | (Yoshida et al. |
| Human immunodeficiency virus (HIV) | Lamivudine (3TC), a deoxycytidine analogue, is used to treat HIV and its combination with 3-deazauridine or acivicin (both are CTPsyn inhibitors) increases anti-HIV activity significantly and halts HIV replication | (Dereuddre-Bosquet et al. |